Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan.
Sign Up to like & getrecommendations! Published in 2022 at "Current drug metabolism"
DOI: 10.2174/1389200224666221212143904
Abstract: BACKGROUND Irinotecan is widely used to treat various types of solid and metastatic cancer. It is an ester prodrug and its hydrolytic metabolite (SN-38) exerts potent anticancer activity. Irinotecan is hydrolyzed primarily by carboxylesterase-2 (CES2),… read more here.
Keywords: covalent ces2; ces2; reduced formation; formation intestinal ... See more keywords